First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma By Ogkologos - March 24, 2026 8 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ILUSTRO study Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR Off Target: Investigating the Abscopal Effect as a Treatment for Cancer January 28, 2020 Study Finds Most Women Who ‘Go Flat’ After Mastectomy Are Happy... January 16, 2021 Cancer Screening Guidelines Often Lack Information on Potential Harms, Study Finds November 23, 2022 Trastuzumab May Improve Survival in Women with Rare Endometrial Cancer August 13, 2020 Load more HOT NEWS Tucatinib and Trastuzumab Combination Approved for Advanced Colorectal Cancer When Cancer Spreads to Bone, A Single Dose of Radiation Therapy... Oncology Dietitians Don’t Usually Inquire About Food Insecurity in Cancer Patients,... Snack Ideas and Tips for Better Sleep
